Strong Revenue Growth
Q4 revenue of $59.9M, up 21.3% YoY; full year revenue $225.2M, up 20.2% YoY, driven by unit volume, mix and continued Avance adoption across target markets.
AxoGen
· AXGN
February 24th, 2026
Summary
- Earnings Call Date:
- 2026-02-24
- Change Since:
- +30.83%
- Next Earnings Date:
- 2026-08-12
Earnings Call Sentiment
PositiveThe call presents materially positive operational and strategic progress: robust revenue growth (Q4 +21.3% YoY; FY +20.2% YoY), a strong capital raise and debt retirement, positive adjusted EBITDA and cash flow for the year, and a transformative FDA BLA approval that establishes Avance as the reference biologic. Near-term challenges include one-time BLA-related noncash charges, elevated operating expenses (notably R&D and G&A), a Q4 net loss and short-term gross margin pressure as the product mix shifts to the biologic. Management provided prudent guidance (≥18% revenue growth for 2026) and expects margin recovery in 2027 as scale and process improvements are implemented. Overall, the highlights outweigh the lowlights given the regulatory milestone, healthy top-line growth, improved adjusted EBITDA and strengthened balance sheet, supporting a constructive outlook despite short-term cost pressure.
Company Guidance
The company guided to at least 18% revenue growth for full-year 2026 — implying revenue of at least $265.7 million (up from $225.2M in 2025, which grew 20.2% YoY) — with full-year gross margin targeted at 74%–76% (consistent with 2025) while noting anticipated product-cost pressure as Avance Biologic sales begin in Q2 2026; management expects to be free-cash-flow positive for the full year (despite higher cash burn in Q1), and reiterated commercial investments including growing the Breast sales force to ~30 reps and Extremities to ~130 reps, high-potential-account objectives of 60% of revenue growth coming from those accounts with 18% productivity improvement and activation of ≥100 surgeons, and 2026 training targets of 10 Extremities programs/200 surgeons, 6 Oral Maxillofacial & Head & Neck programs/100 surgeons, and 5 Breast programs/75 surgeon pairs; for context, 2025 adjusted EBITDA was $27.9M (12.4% margin), Q4 revenue was $59.9M (+21.3% YoY), cash and investments rose $6M to $45.5M year-end, and the company raised $133.3M net proceeds (using $69.7M to retire its term loan).
Adjusted EBITDA and Adjusted Net Income Improvement
Full year adjusted EBITDA grew 41% to $27.9M with margin improving 180 bps to 12.4%; full year adjusted net income increased to $14.4M ($0.29/share) from $5.9M ($0.13/share) in 2024.
Capital Raise and Balance Sheet Strengthening
Completed an upsized public offering raising $133.3M net proceeds in January, used $69.7M to retire the term loan; cash, cash equivalents, restricted cash and investments increased $6M to $45.5M, providing a clean capital structure and enhanced flexibility.
Historic FDA Biologics License Approval (Avance)
December 2025 FDA BLA approval for Avance — the first and only FDA-approved biologic therapeutic for peripheral nerve discontinuities with 12 years of market exclusivity, supporting standard-of-care positioning, payer engagement and prioritized clinical studies.
Commercial Expansion and Sales Force Growth
Expanded commercial organization: Breast added 10 reps (ending with 21 reps), Extremities added 12 reps (ending with 117 reps), added field managers and development staff for OMH&N and Prostate; plans to grow Breast to ~30 reps and Extremities to ~130 in 2026.
Momentum Across Core Markets and Prostate Foundations
Double-digit growth across Extremities, Oral Maxillofacial & Head & Neck and Breast (Breast one of the fastest-growing opportunities); over 100 prostate procedures completed across 10 sites in 2025 with standardized surgical technique established.
High-Potential Account Performance and Surgeon Education
61% of total revenue growth came from high-potential accounts; average high-potential account productivity increased 21%; active surgeons in high-potential accounts increased by 131; training targets exceeded across markets (e.g., Extremities trained 170 surgeons).
Positive Cash Flow Profile and 2026 Guidance
Company was cash flow positive for full year 2025; guiding 2026 revenue growth of at least 18% (≥ $265.7M), gross margin guidance 74%–76%, and expectation to be free cash flow positive for full year 2026.
Operator
Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer. Michael will discuss fourth quarter and full year 2025 financial results and corporate highlights. Lindsey will then provide details on financial performance, guidance and overall outlook for the year. This will be followed by a question-and-answer session. Today's call and presentation is being broadcast live via webcast, which is available on the Investors section of Axogen's website. Following the end of the live call, a replay will be available on the Investors section of the company's website at www.axogeninc.com. Before we begin, I'd like to remind you that during this conference call, management will be making forward-looking statements, which are statements that are not historical facts and are based on current expectations and assumptions regarding future conditions, events and results.
Forward-looking statements include, among other things, statements regarding our financial guidance and outlook, clinical development activities and regulatory efforts, commercial growth initiatives, reimbursement and market access efforts, training and education initiatives, research and development activities and our overall business strategy and operating performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially including, without limitation of risks and uncertainties reflected in our filings with the Securities and Exchange Commission includ...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free